CXCL12 and esophageal cancer: The peptide analog of CXCL12, CTCE-9908, exhibits anti-tumoral effects in in vivo tumor models, including breast, prostate and esophageal cancer, by inhibiting CXCL12-induced primary tumor growth and metastasis [33–36].